# **HEMS** MEDICATION SECTION

# 2-PAM CHLORIDE/DUODOTE

(Protopam Chloride/ Pralidoxime)

Initial Date: 10/25/2017

Revised Date: Section 9-55

## 2-Pam Chloride/DuoDote

#### **Protocols:**

1. Nerve Agent Organophosphate exposure

## Indications:

- 1. Exposure to organophosphate or nerve agents
- 2. Given in conjunction with atropine in DuoDote or Mark-1 kit

#### Contraindications:

1. None

## Dosing:

- 1. Self-Rescue 1 DuoDote (Mark-1) Injector
- 2. Mild Reaction
  - a. Adults (8 years and over) 1 DuoDote (Mark-1) Injector
- Solution
  Description
  Description</
- 3. Moderate Reaction
  - a. Adults (8 years and over) 2 DuoDote (Mark-1) Injectors
- Solution Description 

  Box Street 

  Box
- 4. Severe Reaction
  - a. Adults (8 years and over) 3 DuoDote (Mark-1) Injector

🌇 🔊 b. Pediatrics – 1 DuoDote (Mark-1) Injector, Contact Medical Control as needed

# **Expected Effects:**

1. Decrease in symptoms

#### Side Effects:

- 1. Blurred vision
- 2. Headache
- 3. Dizziness
- 4. Nausea

\*\*Not in Medication Box

MCA Name: HEMS, Inc. (WW/DR) MCA Board Approval Date: 2/8/2024 MCA Implementation Date: 3/1/2024

MDHHS Approval:

Page 1 of 1